MedTrace Logo

Meta-analyses of the Effect of Liquid Meal Replacements on Cardiometabolic Risk

NCT02779790 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2016-05-20

No results posted yet for this study

Summary

Obesity is a major risk factor for cardiovascular disease and diabetes. Weight loss is an important therapeutic goal for overweight and obese patients to reduce their risk of developing cardiovascular disease and diabetes. Liquid meal replacements (LMRs) are simple tools that may aid in weight loss and may improve weight-related risk cardiometabolic risk factors. There is a need to synthesize the evidence on LMRs and cardiometabolic risk to inform clinical practice guidelines. The authors propose to conduct a series of systematic review and meta-analysis of randomized controlled trials to evaluate the effect of LMRs on 4 areas of cardiometabolic risk: markers of adipsoity, glycemic control, established lipid targets, and blood pressure.

Conditions

Interventions

OTHER

Liquid Meal Replacements

An intervention that contains a mixture of protein, carbohydrate, and fat, along with added vitamins and minerals in liquid ready-to-drink or powder formulas that require mixing.

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • The Physicians' Services Incorporated Foundation

    collaborator OTHER

  • Canadian Diabetes Association

    collaborator OTHER

  • Banting & Best Diabetes Centre

    collaborator OTHER

  • John Sievenpiper

    lead OTHER

Principal Investigators

  • John Sievenpiper, MD, PhD, FRCPC · University of Toronto

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2018-01-31
Completion
2018-01-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02779790 on ClinicalTrials.gov